Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2023-03-01

Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes

2022-04-13

Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis

2022-03-14

Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference

2022-01-13

Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

2021-11-03

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

Go Back